Journal
JOURNAL OF PERSONALIZED MEDICINE
Volume 10, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/jpm10040255
Keywords
biomarker; intraoperative imaging; debulking surgery; complete resection; epithelial ovarian cancer; optical imaging; CD24
Funding
- Helse Vest RHF
- Helse Bergen HF [911809, 911852, 912171, 240222, HV1269]
- Norwegian Cancer Society [182735]
- Research Council of Norway through its Centers of excellence funding scheme [223250, 262652]
Ask authors/readers for more resources
Complete cytoreductive surgery is the cornerstone of the treatment of epithelial ovarian cancer (EOC). The application of fluorescence image-guided surgery (FIGS) allows for the increased intraoperative visualization and delineation of malignant lesions by using fluorescently labeled targeting biomarkers, thereby improving intraoperative guidance. CD24, a small glycophosphatidylinositol-anchored cell surface receptor, is overexpressed in approximately 70% of solid cancers, and has been proposed as a prognostic and therapeutic tumor-specific biomarker for EOC. Recently, preclinical studies have demonstrated the benefit of CD24-targeted contrast agents for non-invasive fluorescence imaging, as well as improved tumor resection by employing CD24-targeted FIGS in orthotopic patient-derived xenograft models of EOC. The successful detection of miniscule metastases denotes CD24 as a promising biomarker for the application of fluorescence-guided surgery in EOC patients. The aim of this review is to present the clinical and preclinically evaluated biomarkers for ovarian cancer FIGS, highlight the strengths of CD24, and propose a future bimodal approach combining CD24-targeted fluorescence imaging with radionuclide detection and targeted therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available